All lobbying filings

THE WASHINGTON TAX & PUBLIC POLICY GROUP

Lobbying for ALLIANCE FOR BIOPHARMACEUTICAL COMPETITIVENESS AND INNOVATION · Biopharmaceutical industry

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $70,000.00 income · posted Jul 8, 2025

Official filing document

Bills named in this filing 10

HR 1990
American Innovation and R&D Competitiveness Act of 2025
HR 574
ALIGN Act
HR 1062
Growing and Preserving Innovation in America Act of 2025
S 187
ALIGN Act
S 1605
International Competition for American Jobs Act
S 2021
Close the Round-Tripping Loophole Act
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 1347
AIMM Act
S 559
AIMM Act
S 1688
Growing America’s Small Businesses and Manufacturing Act

Lobbying activity 1

Taxation/Internal Revenue Code

Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on the tax base of the U.S. and its Territories. Issues related to IRC sections 11, 164(a), 951A, 250, 59A, 163(j), 168(k), 174, and 41. (H.R.1990, H.R. 574, H.R. 1062, S. 187, S. 1605, S. 2021, H.R. 1 - Sections 70301, 70302, 70321, 70322, 70323, 70331, 70361). Issues related to interest deductibility. (H.R. 1347, S. 559, S. 1688, H.R. 1 - Section 70303)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.